Table 2.

The number of ACF in DMH-treated rats with and without FDLE administration in initiation stage.

Treatment	Number of ACF/rata				Aberrant crypt/focus
	Proximal	Distal	Rectal	Total colon (% inhibition)
NSS (Gr.1)	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0
DMH (Gr.2)	115 ± 30	100 ± 32	26 ± 10	241 ± 69	1.6 ± 0.1
DMH + 100 mg/kg bw FDLE (Gr.3)	117 ± 29	93 ± 26	18 ± 9	227 ± 58 (5.8%)	1.5 ± 0.1
DMH + 500 mg/kg bw FDLE (Gr.4)	70 ± 24*	57 ± 15*	23 ± 10	151 ± 41* (37.3%)	1.7 ± 0.1
NSS + 500 mg/kg bw FDLE (Gr.5)	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0

^aMean ± SD of 6 rats per group, *p < 0.05; Significantly different from Gr.2.